Differentiation of human embryonic germ cells and transplantation in rats with acute myocardial infarction

SHUICHANG YU1*, YANBO ZHU2*, FANG LI1, YUJUAN ZHANG1 and CHUNLIN XIA3

1Department of Histology and Embryology, Medical College of Soochow University, Suzhou 215123;  
2Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006;  
3Boxi Institute of Clinical Anatomy and Cytoneurobiology Laboratory, Medical College of Soochow University, Suzhou 215123, P.R. China

Received August 15, 2013; Accepted December 19, 2013

DOI: 10.3892/etm.2014.1474

Abstract. Human embryonic germ cells (hEGCs) are stem cells cultured from primordial germ cells, which reside in human embryonic genital ridges in vivo. In this study, hEGCs were induced to differentiate into cardiomyocytes by treatment with ascorbic acid in vitro and the effects of hEGC transplantation on rat models of acute myocardial infarction (AMI) were investigated. hEGCs were incubated with differentiation medium containing ascorbic acid at various concentrations. Levels of GATA-4 expression were measured to identify the optimal concentration of the inductor. Immunofluorescence microscopy was used to detect the expression of Cx43 on the induced cells. The hEGCs were injected into the myocardium of rats with AMI. The expression levels of MAB1281 and GATA-4 were used to indicate the survival, migration, distribution and differentiation of transplanted cells. The results revealed the positive expression of GATA-4, Cx43 and cardiac troponin T (cTnT) in differentiated cells, and immunocytochemistry showed that transplanted cells highly expressed GATA-4 and MAB1281. hEGCs were successfully induced to differentiate into cardiomyocytes by ascorbic acid in optimal concentrations in vitro and the transplanted hEGCs survived and differentiated into cardiomyocytes.

Introduction

Acute myocardial infarction (AMI) is an issue worldwide, which severely jeopardises human health. The majority of patients who suffer from AMI succumb to its complications, such as heart failure and arrhythmias. The mechanisms involved in repairing the infarcted zone remain unknown. Cell therapy of AMI involves transplanting various types of stem cells that have the potential to differentiate in the infarcted zone, where they proliferate and differentiate into cardiomyocytes, thus improving heart function (1,2).

Embryonic stem cells (ESCs) have the ability to respond to environmental demands. Previous studies have shown that retinoic acid induces the differentiation of ESCs into cardiomyocytes. Inductors also include dimethyl sulphoxide (DMSO), cAMP, neuregulin and deoxycytidine (3-6). Rajasingh et al found that leukaemia inhibitory factor (LIF) and bone morpho- genetic protein 2 (BMP-2) were able to synergistically enhance the cardiomyocyte differentiation of transplanted stem cells, whereas DMSO or retinoic acid were not (7). In addition to using inductors, investigators have precipitated the differentiation of ESCs into cardiomyocytes naturally. Kehat et al observed that cardiomyocytes differentiated from ESCs have the characteristics of myocardial electrophysiology and surface proteins. The authors transplanted these cardiomyocytes into the infarcted zone of a pig and found that these cells integrated with the receptor cardiomyocytes, and the heart began to beat again (8).

Human embryonic germ cells (hEGCs) are stem cells cultured from primordial germ cells, which reside in human embryonic genital ridges in vivo. They are similar to human embryonic stem cells (hESCs), which form the inner cell mass, in biological characteristics. Our laboratory has established a system for obtaining hEGCs through tissue culturing. The study of hESC transplantation for the treatment of AMI started worldwide >10 years ago; however, the use of hEGCs as a transplantable cell source for treating AMI has not, to the best of our knowledge, been reported.

In the present study, ascorbic acid was used to induce hEGCs to differentiate into cardiomyocytes in vitro with the aim of identifying a simple and high-performance empirical method for promoting hEGC differentiation. In addition, hEGCs were injected into the infarcted zone in rat models of AMI in order to observe and identify the survival and differentiation of hEGCs, thereby providing experimental support for myocardial tissue engineering research and the treatment of AMI by stem cell transplantation.
Materials and methods

Main reagents. The reagents used in this study were as follows: Dulbecco's modified Eagle's Medium (DMEM; Gibco-BRL, Carlsbad, CA, USA; high glucose); fetal calf serum (FCS; Hyclone, Beijing, China); basic fibroblast growth factor (bFGF); LIF; ascorbic acid, and Cx43 and cardiac troponin T (cTnT) mouse anti-human monoclonal antibodies (R&D Systems, Shanghai, China); FITC-labeled rabbit anti-mouse secondary antibody (Wuhan Boster Biological Technology, Ltd., Wuhan, China); MAB1281 mouse anti-human nuclei monoclonal antibody (Chemicon, Temecula, CA, USA); rabbit anti-GATA-4 (Wuhan Boster Biological Technology, Ltd.); and EnVision™ Detection kit (GK50075; comprising ChemMate™ DAKO EnVision™/HRP, Rabbit/Mouse(ENV); ChemMate™ Substrate Buffer and ChemMate™ 3,3'-diaminobenzidine (DAB) + Chromogen; Genentech, Inc., San Francisco, CA, USA); Hoechst33342 Cell Staining solution (Biohao, Beijing, China).

Source of embryos. Human embryos aborted at 5-10 weeks, were collected from The First and Second Hospitals Affiliated to Soochow University (Suzhou, China) and the Maternal and Child Health Center (Suzhou, China), with the permission from pregnant women and the Morality Committee. All the embryos were intact and not severely contaminated.

Cell culture and proliferation of hEGCs. The gonadal ridges of 5-10-week-old embryos were cultured as explant tissue in vitro, in high glucose DMEM supplemented with 15% FCS; LIF and bFGF were also added. The hEGCs and cell cultures were gained from the surface of the homologous human embryonic fibroblast, which was used as the feeder. After 8 days of primary culture, the hEGCs were digested and subcultured to passage 4.

Formation of embryoid bodies (EBs) by suspension culture. The subconfluent cells were selected for digestion into a single cell suspension, then plated onto a gelatin (0.1%)-coated 100-mm Petri dish at 37°C in humid air with 5% CO₂ for 1 h to remove fibroblasts. Briefly, 1x10⁶ cells in 1 ml cultivation medium containing 20% FCS were suspended in bacteriological plates for 5 days. The medium was replaced every other day.

Differentiation of hEGCs into cardiomyocytes. After suspension for 5 days, EBs were separately plated onto a gelatin (0.1%)-coated 24-well plate and various concentrations (0.01, 0.05, 0.1 and 0.2 mg/ml) of ascorbic acid were added. The medium was replaced with fresh medium every other day.

Immunocytochemistry. Cells were collected at 1, 2, 3 and 4 weeks of induction and fixed in 4% paraformaldehyde, quenched with 3% hydrogen peroxide and non-specific background was blocked with a serum-free blocking solution. Primary antibodies were diluted in dilution buffer and incubated with the cells for 30 min at room temperature. Cells were washed in phosphate-buffered saline and a polymer-linked peroxidase-labeled secondary antibody was added for 30 min at room temperature. Cells were then stained with DAB and haematoxylin, fixed with neutral gum and photographed. Cardiomyocytes were identified immunochemically using anti-GATA-4 and anti-cTnT antibodies. Controls underwent staining without the primary antibody.

Statistical analysis. Conversion rate of cardiac-like cells: three visual fields of the cell creep slices induced by the inducers were recorded. The total cell count and the count of cells positive for GATA-4 were recorded under a light microscope with a magnification of x200 (Olympus, Shanghai, China). The conversion rate of hEGC differentiation into cardiac-like cells in the three fields was calculated. Results are expressed as the means ± standard deviation and statistically evaluated by Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Immunofluorescence. Cells were collected following induction for 2 weeks, and the expression levels of myocardial connectin Cx43 protein and cardiac troponin (cTnT) were detected by immunofluorescence. Cells were blocked by treatment with cold methanol in PBS for 30 min. After rinsing three times in PBS for 5 min each, rat anti-human (1:50) antibody diluted solution was added overnight at 4°C. Cells were rinsed three times in PBS for 5 min each. Subsequently, the cells were incubated with FITC-labeled rabbit anti-mouse secondary antibody at a dilution of 1:50 in PBS for 1 h at room temperature. Cells were rinsed three times in PBS for 5 min each. Cells were then covered with 50% buffered glycerol and observed under a fluorescence microscope (Olympus).

Experimental animals and grouping. Forty Sprague-Dawley rats, of clean grade and either gender (weight, 200-250 g) were provided by the Experimental Animal Center of Soochow University (Suzhou, China). These rats were randomly divided into two groups: The experimental group (n=28) and the control group (n=12). In the experimental group, hEGCs were injected into the edge of the infarcted zone of the rat models with AMI. Four points were selected and 12 µl cell suspension was injected into each point. In the control group, the same process was followed but only PBS was injected into the selected points to serve as the negative control.

Preparation of the cells for transplantation. One hour prior to transplantation, the hEGC colony subcultured to the fourth passage was extracted with aseptic inoculating needles, and digested with 0.25% trypsinase and 0.02% EDTA. When cytoplasm recovery occurred and the cell colonies were scattered, blood serum medium was added to stop the trypsinization, and then a pipette was used to blow air across the cells and to strike the bottom of the bottle gently and repeatedly until the cells formed a steady cell suspension. The cells were centrifuged for 5 min at 1,000 x g, washed with sterile PBS and then blown on and struck until the cells were well distributed for cell counting. The cells were taken up with a microinjector at a concentration of 1x10⁶ ml (50 µl).

Establishment of the rat model of myocardial infarction. The surgery group: The AMI model was established by ligation of the left anterior descending branch of the coronary artery. Rats were anesthetized with an intraperitoneal injection of 4% chloral hydrate and, following disinfection of the surgical area, tracheal intubation was performed and mechanical
ventilation was initiated. With monitoring by electrocardiography (CONTEC), the thoracic cavity was opened from the left sternal border in the third or fourth intercostal muscles and the cardiac pericardium was opened until the heart was totally exposed. The left anterior descending branch of the coronary artery was ligated with 5.0 surgical silk sutures. Needle-shaped electrodes were attached under the four limbs. Lead II electrocardiograms (ECGs) were recorded. The myocardial infarction model was established until persistent ST elevation on the ECG indicative of myocardial infarction was observed. After the surgery, 400,000 units penicillin was injected into the rats in case of infection. The rats recovered at 30˚C. Strict aseptic conditions were maintained during the whole process; therefore, dermal sutures were unnecessary. The sham surgery group: Between the lower margin of the left atrial appendage and pulmonary conus, namely the left anterior descending branch of the coronary artery, a non-invasive suture needle was used to perforate the lower part of the blood vessel without ligature. Other procedures were similar to those in the surgery group.

Transplantation of hEGCs following myocardial infarction. The prepared hEGC suspension was directly injected into the infarcted zone in the heart of each rat. Under direct vision, after the ligature was removed from the anterior descending coronary artery, hEGCs were injected into the edge of the infarcted zone of the heart. Four points were selected and 12 µl cell suspension with a concentration of 1x10⁶/ml was injected into each. In the control group, the same process was followed, but only PBS was injected into the selected points to serve as the negative control. The pectus was closed and mechanical ventilation was maintained until spontaneous respiration occurred.

Immunohistochemistry. One day and 1, 2 and 4 weeks following the transplantation, seven rats in the experimental group and three in the control group were selected. The rats were anaesthetised with an intraperitoneal injection of 4% hydral and their hearts were removed and washed in PBS. The left and right atria of the heart together with the right ventricle were eliminated, the left ventricle was fixed with 4% paraformaldehyde and embedded in paraffin for serial sectioning. Primary antibodies against MAB1281 (1:100) and GATA-4 (1:100), as well as universal secondary antibodies were adopted in a 2-step immunohistochemical method (5). Cells were observed under a microscope (Olympus). All processes were conducted strictly according to the manufacturer's instructions.

Results

Characteristics of cells following induction. Spindle-shaped and irregular cells increased in number at the periphery of EBs after 1 week (Fig. 1A). Prominences in flanking cells were connected after 2 weeks (Fig. 1B). The connections between adjacent cells became apparent and formed an intercalated-like structure after 3 weeks (Fig. 1C). The cells tended to be uniform after 4 weeks of treatment with 0.05 or 0.1 mg/ml ascorbic acid (Fig. 1D). The cell morphology did not change significantly following treatment with 0.01 mg/ml ascorbic acid; however, the majority of cells died under treatment with 0.2 mg/ml ascorbic acid.

Optimal induction concentration. The effective concentration of ascorbic acid was 0.01-0.1 mg/ml and the inductive effect was dose-dependent. Comparisons in the conversion rates of the experimental and control groups revealed significant differences (P<0.01). Significant differences were also observed
between the conversion rates at all time points (P<0.05) with the highest conversion rate at 3 weeks. Comparisons of the results for 0.1 mg/ml ascorbic acid with those of 0.05 and 0.01 mg/ml revealed significant differences (P<0.05). The results showed that the optimum concentration of ascorbic acid was 0.1 mg/ml (Table I).

Expression of GATA-4 and cTnT detected by immunocytochemistry. Following treatment with 0.1 mg/ml ascorbic acid, the primordial myocardium-specific transcription factor, GATA-4, was stained positively in the differentiated cells after 1 week of induction; however, the positive cell number was low and brownish yellow granules were observed (Fig. 2A). An increased number of positive cells were stained 2 weeks following induction; the nucleus appeared oval-shape and stained brown in color (Fig. 2B). The expression of GATA-4 peaked after 3 weeks; the nucleus was long fusiform in shape and presented dark brown (Fig. 2C). The positive cell number decreased gradually and tended to be uniform after 4 weeks of induction (Fig. 2D). No expression of GATA-4 was observed in the normal tissue group (Fig. 2E).

Following treatment with 0.1 mg/ml ascorbic acid, cTnT expression was not observed until 2 weeks after induction and the expression was weak and the endochylema was stained brownish yellow (Fig. 2F and G). cTnT expression increased gradually over 3 and 4 weeks. cTnT was stained brown around the nucleus after 3 weeks of induction (Fig. 2H and I). No expression of cTnT was detected in the normal tissue group (Fig. 2J).

Immunofluorescence of differentiated cardiomyocytes. Following treatment with 0.1 mg/ml ascorbic acid, the immunofluorescence assay showed that after induction for 2 weeks, numerous Cx43-stained cells emitted strong red fluorescence. The cells were polygonal and spindle-shaped (Fig. 2K). In the control group, the nuclei were stained blue with Hoechst 33342 (Fig. 2L).

Rat model of AMI. After ligation of the left anterior descending artery in the surgery group, the distal end cardiac muscles of ligation were significantly pallid and their activity was weakened or disappeared at a certain range (Fig. 3A). The ECG showed limb lead ST-segment elevation to various degrees in the surgery group after 1-20 min of ligation and the pathological Q wave appeared (Fig. 3B). The sham surgery group were normal.

Results of MAB1281 and GATA-4 immunohistochemistry. One day after transplantation, MAB1281-positive cells were distributed along the epicardium; the cells appeared round with a deep brown nucleus and were arranged in a disorderly manner (Fig. 4A). One week following transplantation, cardiac muscles in the infarcted zone showed necrosis and were disordered. There were MAB1281-positive cells around the myocardium, and cells were spindle-shaped and thin (Fig. 4B). Two weeks after transplantation, MAB1281-positive cells were arranged in the infarcted zone of the myocardium and were parallel to the cardiac muscles. They were long and spindle-shaped with a brown ovoid nucleus (Fig. 4C). Four weeks after transplantation, the majority of the cells in the infarcted zone were MAB1281 positive with a short column and brown nucleus, and the cardiomyocytes were aligned (Fig. 4D). The control group was negative for MAB1281 (Fig. 4E).

One day following transplantation, GATA-4-positive cells were dispersedly distributed under the epicardium and appeared round with a deep brown nucleus and a small amount of cytoplasm (Fig. 4F). One week after transplantation, GATA-4-positive cells were observed in the infarcted zone of the myocardium and along blood vessels; the cells were thin and spindle-shaped with a brown nucleus (Fig. 4G). Two weeks after transplantation, GATA-4-positive cells were arranged in the infarcted zone of the myocardium and were parallel with the cardiac muscles; the cells appeared long and spindle-shaped with a brown ovoid nucleus (Fig. 4H). Four weeks after transplantation, most cells of the infarcted zone were positive for GATA-4, had a short column and brown nucleus, and the cardiomyocytes were aligned in order (Fig. 4I). The control group was negative for GATA-4 expression (Fig. 4J).

Discussion

Doetschman et al observed that, under certain conditions, ESCs rapidly differentiate into cardiomyocytes with a spontaneous rhythmic contraction; therefore, ESCs have become a useful tool for studying gene expression and heart function (9). It has been shown that differentiated cells in vitro are similar to cardiomyocytes in vivo in electrophysiological aspects and the cell cycle, which is indicative of broad prospects for the future of cardiomyocyte transplantation therapy (10). One of the major findings of the present study was that ascorbic acid served as a valuable inducer for the cardiac differentiation of hEGCs with

Table I. Conversion rate of cardiac-like cells of hEGCs treated with ascorbic acid (%).

| Groups            | Concentration of ascorbic acid (mg/ml) | 1 week   | 2 weeks   | 3 weeks   | 4 weeks   |
|-------------------|----------------------------------------|----------|-----------|-----------|-----------|
| Control           | 0.00                                   | 0        | 0         | 0         | 0         |
| Experimental      | 0.01                                   | 26.7±4.17a | 37.5±0.65a | 54.5±1.73a | 38.0±3.27a |
|                   | 0.05                                   | 41.3±2.34a | 67.0±3.11a | 80.6±3.35a | 62.2±6.01a |
|                   | 0.10                                   | 46.0±2.01a | 71.3±1.36a | 85.2±1.79a | 77.4±1.49a |
|                   | 0.20                                   | 0        | 0         | 0         | 0         |

*aP<0.01, comparison between the experimental group and the control group and between all time points (P<0.05). hEGCs, human embryonic germ cells.
Figure 2. (A-E) Expression of the primordial myocardium-specific transcription factor, GATA-4, in hEGCs treated with 0.1 mg/ml ascorbic acid for 1-4 weeks (A-D) and in the control group (E) by immunocytochemistry staining; (F-J) expression of cardiac troponin T (cTnT) in hEGCs treated with 0.1 mg/ml ascorbic acid after 1-4 weeks (F-I) and in the control group (J) by immunocytochemistry staining; (K,L) expression of Cx43 by immunofluorescence in hEGCs treated with 0.1 mg/ml ascorbic acid for 2 weeks (K) and in the control group (L). Magnification, x200. hEGCs, human embryonic germ cells.

Figure 3. (A) Myocardial infarction in rats was observed under a dissecting microscope. (B) Changes consistent with myocardial infarction were observed in the rat model of myocardial infarction by electrocardiography.

Figure 4. (A-E) Expression of MAB1281 in transplanted cells after 1 day and 1, 2 and 4 weeks (A-D) and in the control group (E) by immunohistochemical staining; and (F-J) expression of GATA-4 in transplanted cells after 1 day and 1, 2 and 4 weeks (F-I) and in the control group (J) by immunohistochemical staining. Magnification, x100.
high efficiency and efficacy in vitro. hEGCs differentiated into cardiomyocytes following treatment with ascorbic acid within a certain concentration range (0.05-0.1 mg/ml). The majority of cells died when the concentration reached 0.2 mg/ml due to the low pH and the precipitation of crystals. Therefore, hEGCs were treated with 0.1 mg/ml ascorbic acid and cardiomyocyte-like cells were obtained, which proliferated rapidly reaching a maximum at 10-12 days after induction. The immunofluorescence assay detected expression of Cx43 and cTnT in the cardiomyocyte-like cells.

A large reduction in the number of cardiomyocytes following myocardial infarction results in anatomical changes of the heart and remodeling of the left ventricle, ultimately resulting in heart failure. No type of reconstruction of the blood supply to the coronary artery or further medical treatment is able to prevent the loss of cardiomyocytes and left ventricular remodeling. However, transplantation of stem cells enables the regeneration of cardiomyocytes with normal function, thus inhibiting the formation of scar tissues and improving the cardiac function (11). A study has also shown the ability of hESC-derived cardiomyocyte transplantation to attenuate following transplantation the hEGCs gradually migrated into the myocardium, mostly to the infarcted zone with only a few migrating to the normal region in the heart. In the control group, rats were injected with the same volume of PBS and no expression of MAB1281 cells was detected.

Studies have shown that many tissue-specific transcription factors are associated with heart development, such as GATA-4, NKx2.5, Hey2, c-myb, Sox6 and Tbx (13-16), among which GATA-4 is the most closely associated. GATA-4 has been found to induce stem cell differentiation to cardiomyocytes, playing an important role in heart development at the early stage and it is also the earliest sign of cardiomyocyte progenitor cells. ESCs expressing GATA-4 may only differentiate to cardiomyocytes (17-20). In this study, hEGCs were transplanted into the infarcted zone of rats with myocardial infarction and 1 day and 1, 2 and 4 weeks later, positive expression of GATA-4 was observed in the progenitor cells, mainly in the nuclei. The number of GATA-4 positive cells increased with time. There was no expression in the control group. The data presented in the present study suggest that hEGCs survive after transplantation, then differentiate into cardiomyocyte progenitor cells. As the treatment was prolonged, the cells transplanted into the infarcted zone were arranged in an orderly manner, and were spindle-like, short and cylindrical in shape, which indicated that the cells began to differentiate to cardiomyocytes with a normal structure. Thus, the potential to treat myocardial infarction was demonstrated.

References

1. Müller-Ehmsen J, Kedes LH, Schwinger RH and Kloner RA: Cellular cardiomyoplasty—a novel approach to treat heart disease. Congest Heart Fail 8: 220-227, 2002.

2. Lecina M, Ting S, Choo A, Reaveny S and Oh S: Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures. Tissue Eng Part A 16: 169-178, 2010.

3. Wobus AM, Kaomei G, Shan J, Wellner MC, Rohwedel J, Ji GI, Fleischmann B, Katus HA, Hescheler J and Franz WM: Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J Mol Cell Cardiol 29: 1525-1539, 1997.

4. Sup M, Yan X, Bian Y, Caggiano AO and Morgan JP: Improving murine embryonic stem cell differentiation into cardiomyocytes with neurulin-1: differential expression of microRNA. Am J Physiol Cell Physiol 301: C21–C30, 2011.

5. Chen Y, Shao JZ, Xiang LX, Guo J, Zhou QJ, Yao X, Dai LC and Xi Y: Cyclic adenosine 3′,5′-monophosphate induces differentiation of mouse embryonic stem cells into cardiomyocytes. Cell Biol Int 30: 301-307, 2006.

6. Xu C, Police S, Rao N and Carpenter MK: Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 91: 501-508, 2002.

7. Rajasingsh J, Bord E, Hamada H, Lambers E, Qin G, Losordo DW and Kishore R: STAT3-dependent mouse embryonic stem cell differentiation into cardiomyocytes: analysis of molecular signaling and therapeutic efficacy of cardiomyocyte precommitted mES transplantation in a mouse model of myocardial infarction. Circ Res 101: 918-928, 2007.

8. Kehat I, Kimovich L, Caspi O, Gepstein A, Shofft R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J and Gepstein L: Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 22: 1282-1289, 2004.

9. Doetschman T, Eisterer H, Katz M, Schmidt W and Kemler R: The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87: 27-45, 1985.

10. Westfall MV, Pasyk KA, Yule DI, Samuelson LC and Metzger JM: Ultrastructure and cell-cell coupling of cardiomyocytes differentiating in embryonic stem cell cultures. Cell Motil Cytoskeleton 36: 43-54, 1997.

11. Sargent CY, Berguis GC and McDevitt TC: Cardiomyogenic differentiation of embryoid bodies is promoted by rotary orbital suspension culture. Tissue Eng Part A 15: 331-342, 2009.

12. Leor J, Gerecht S, Cohen S, Miller L, Holbova R, Ziskind A, Shachar M, Feinberg MS, Guetta E and Itskovitz-Eldor J: Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart 93: 1278-1284, 2007.

13. Liberatore CM, Searcy-Schrick RD and Yatzey KE: Ventricular expression of tbx5 inhibits normal heart chamber development. Dev Biol 223: 169-180, 2000.

14. Turbendian HK, Gordillo M, Tsai SY, Lu J, Kang G, Liu TC, Tang A, Liu S, Fishman GI and Evans T: GATA factors efficiently direct cardiac fate from embryonic stem cells. Development 140: 6341-6344, 2013.

15. Cohen-Barak O, Yi ZH, Hagiwara N, Monzen K, Komuro I and Brilliant MH: Sox6 regulation of cardiac myocyte development. Nucleic Acids Res 31: 5941-5948, 2003.

16. Ishida M, El-Mounayri O, Kattman S, Zandstra P, Sakamoto H, Ogawa M, Keller G and Husain M: Regulated expression and role of c-Myb in the cardiovascular-directed differentiation of murine embryonic stem cells. Circ Res 110: 253-264, 2012.

17. Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, Huggins GR and Gearhart JD: Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 95: 13726-13731, 1998.

18. Snyder M, Huang XY and Zhang JJ: STAT3 directly controls the expression of Tbxa2, Cx43 and cTnT in the myocardium. J Mol Cell Cardiol 29: 1525-1539, 1997.

19. Derivation of pluripotent stem cells from cultured human embryonic germ cells. Circ Res 110: 253-264, 2012.

20. Ogawa M, Keller G and Husain M: Regulated expression and role of tbx5 inhibits normal heart chamber development. Dev Biol 36: 43-54, 1997.

21. Sargent CY, Berguis GC and McDevitt TC: Cardiomyogenic differentiation of embryoid bodies is promoted by rotary orbital suspension culture. Tissue Eng Part A 15: 331-342, 2009.

22. Leor J, Gerecht S, Cohen S, Miller L, Holbova R, Ziskind A, Shachar M, Feinberg MS, Guetta E and Itskovitz-Eldor J: Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart 93: 1278-1284, 2007.

23. Liberatore CM, Searcy-Schrick RD and Yatzey KE: Ventricular expression of tbx5 inhibits normal heart chamber development. Dev Biol 223: 169-180, 2000.

24. Turbendian HK, Gordillo M, Tsai SY, Lu J, Kang G, Liu TC, Tang A, Liu S, Fishman GI and Evans T: GATA factors efficiently direct cardiac fate from embryonic stem cells. Development 140: 6341-6344, 2013.

25. Cohen-Barak O, Yi ZH, Hagiwara N, Monzen K, Komuro I and Brilliant MH: Sox6 regulation of cardiac myocyte development. Nucleic Acids Res 31: 5941-5948, 2003.

26. Ishida M, El-Mounayri O, Kattman S, Zandstra P, Sakamoto H, Ogawa M, Keller G and Husain M: Regulated expression and role of c-Myb in the cardiovascular-directed differentiation of murine embryonic stem cells. Circ Res 110: 253-264, 2012.

27. Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, Huggins GR and Gearhart JD: Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 95: 13726-13731, 1998.

28. Snyder M, Huang XY and Zhang JJ: Stat3 directly controls the expression of Tbx5, Nkx2.5, and GATA4 and is essential for cardiomyocyte differentiation of P19CL6 cells. J Biol Chem 285: 23639-23646, 2010.

29. Stennard FA, Costa MW, Elliott DA, Rankin S, Haast SJ, Lai D, McDonald LP, Niederreither K, Dolle P, Bruneau BG, Zorn AM and Harper RP: Cardiac T-box factor Tbx20 directly interacts with Nkx2.5, GATA4, and GATA5 in regulation of gene expression in the developing heart. Dev Biol 262: 206-224, 2003.

30. Small EM and Krieg PA: Transgenic analysis of the atrialnatriuretic factor (ANF) promoter: Nkx2.5 and GATA-4 binding sites are required for atrial specific expression of ANF. Dev Biol 261: 116-131, 2003.